A new T-cell treatment for acute myeloid leukemia after transplant
Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease
This project explores a new T-cell treatment designed to prevent acute myeloid leukemia from returning in people who have had a stem cell transplant.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Marker Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11042150 on NIH RePORTER |
What this research studies
Acute myeloid leukemia (AML) can sometimes come back after a stem cell transplant, which is a major concern for patients. This new approach uses special T-cells, called MT-401, that are trained to recognize and fight multiple markers on leukemia cells at the same time. These T-cells are made from the same donor who provided the stem cells for the transplant. By targeting several markers, this treatment aims to make it harder for leukemia cells to hide or escape the immune system, offering a new way to keep the cancer from returning.
Who could benefit from this research
Good fit: Ideal candidates are patients with acute myeloid leukemia who have recently undergone an allogeneic stem cell transplant and still have minimal signs of the disease.
Not a fit: Patients who have not received an allogeneic stem cell transplant or who do not have acute myeloid leukemia would not benefit from this specific treatment.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce the risk of AML relapse after a stem cell transplant, improving long-term survival for patients.
How similar studies have performed: While T-cell therapies have shown promise in other cancers, this specific multi-antigen approach for AML after transplant is a novel strategy being tested.
Where this research is happening
Houston, United States
- Marker Therapeutics, INC. — Houston, United States (Active)
Researchers
- Principal investigator: Vera, Juan Fernando — Marker Therapeutics, INC.
- Study coordinator: Vera, Juan Fernando
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.